{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:46:15Z","timestamp":1791819975929,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Government of Catalonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijid.2026.109010","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:25:34Z","timestamp":1785194734000},"page":"109010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacometric analyses of various ivermectin dose regimens in Kenya to inform dosing in mass drug administration trials for malaria vector control"],"prefix":"10.1016","volume":"171","author":[{"given":"Charlotte","family":"Kern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Kamau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Ominde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Tuwei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Karisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Adetifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina N.","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Chaccour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Duthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-9330","authenticated-orcid":false,"given":"Felix","family":"Hammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.109010_sbref0001","series-title":"World Malaria Report 2025: addressing the threat of antimalarial drug resistance","year":"2025"},{"key":"10.1016\/j.ijid.2026.109010_bib0002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13063-023-07098-2","volume":"24","author":"Chaccour","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.ijid.2026.109010_bib0004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.pt.2014.07.005","article-title":"Ivermectin: panacea for resource-poor communities?","volume":"30","author":"Omura","year":"2014","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijid.2026.109010_bib0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S1473-3099(18)30176-2","article-title":"Ivermectin: repurposing an old drug to complement malaria vector control","volume":"18","author":"Rabinovich","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4269\/ajtmh.19-0620","article-title":"A roadmap for the development of ivermectin as a complementary malaria vector control tool","volume":"102","author":"Billingsley","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2026.109010_bib0007","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(18)30163-4","article-title":"Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Smit","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0008","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12936-017-1801-4","article-title":"Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety","volume":"16","author":"Chaccour","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2026.109010_bib0009","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/1475-2875-13-417","article-title":"Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments","volume":"13","author":"Alout","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2026.109010_bib0010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(19)30633-4","article-title":"Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study","volume":"20","author":"Slater","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0011","unstructured":"World Health Organization. Alternative mass drug administration regimens to eliminate lymphatic filariasis. [accessed 16 April 2026]. https:\/\/www.who.int\/publications\/i\/item\/9789241550161."},{"key":"10.1016\/j.ijid.2026.109010_bib0012","unstructured":"World Health Organization. Ivermectin for malaria transmission control (Technical consultation Meeting Report of the Malaria Policy Advisory Committee Meeting, Sep. 14\u201316 2016). [accessed 16 April 2026]. https:\/\/www.who.int\/publications\/m\/item\/WHO-HTM-GMP-MPAC-2016.11."},{"key":"10.1016\/j.ijid.2026.109010_bib0013","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa2411262","article-title":"Ivermectin to control malaria \u2014 a cluster-randomized trial","volume":"393","author":"Chaccour","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.109010_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107236","article-title":"Mosquitocidal efficacy and pharmacokinetics of single-dose ivermectin versus three-day dose regimen for malaria vector control compared with albendazole and no treatment: an open-label randomized controlled trial","volume":"148","author":"Kamau","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0015","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/psp4.13038","article-title":"Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania","volume":"12","author":"Fimbo","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijid.2026.109010_bib0016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/cpt.3424","article-title":"Population pharmacokinetics and exposure-response analysis of a fixed-dose combination of ivermectin and albendazole in children, adolescents, and adults","volume":"117","author":"Algorta","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2026.109010_bib0017","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cpt.1456","article-title":"Ivermectin dosing strategy to achieve equivalent exposure coverage in children and adults","volume":"106","author":"Brussee","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2026.109010_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008886","article-title":"Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children","volume":"14","author":"Gwee","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0019","first-page":"79","article-title":"Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus","volume":"42","author":"Elkassaby","year":"1991","journal-title":"Trop Med Parasitol"},{"key":"10.1016\/j.ijid.2026.109010_bib0020","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jac\/dkz083","article-title":"Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2\u201312 years","volume":"74","author":"Schulz","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.109010_bib0021","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bcp.13840","article-title":"Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers","volume":"85","author":"Duthaler","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2026.109010_bib0022","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpt.1219","article-title":"Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL)","volume":"105","author":"Smit","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2026.109010_bib0023","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cpt.1716","article-title":"Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects","volume":"107","author":"Kobylinski","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2026.109010_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jpba.2019.04.007","article-title":"Development and validation of an LC-MS\/MS method for the analysis of ivermectin in plasma, whole blood, and dried blood spots using a fully automatic extraction system","volume":"172","author":"Duthaler","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ijid.2026.109010_bib0026","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00316107","article-title":"Ivermectin binds avidly to plasma proteins","volume":"39","author":"Klotz","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2026.109010_bib0027","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/jac\/dky254","article-title":"Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions","volume":"73","author":"Duthaler","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.109010_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijid.2026.109010_bib0029","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ijid.2026.109010_bib0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics","volume":"30","author":"Holford","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2026.109010_bib0031","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12936-023-04624-0","article-title":"Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes","volume":"22","author":"Kern","year":"2023","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2026.109010_bib0032","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1038\/s41598-023-34719-2","article-title":"Ivermectin metabolites reduce Anopheles survival","volume":"13","author":"Kobylinski","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.109010_bib0033","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jcph.6158","article-title":"Pharmacometric analysis to describe pharmacokinetics and exposure-efficacy response of ivermectin in adolescents infected with Trichuris trichiura","volume":"65","author":"Ajayi","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2026.109010_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011319","article-title":"Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis","volume":"17","author":"Alshehri","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0035","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.xphs.2018.03.026","article-title":"The repurposing of ivermectin for malaria: a prospective pharmacokinetics-based virtual clinical trials assessment of dosing regimen options","volume":"107","author":"Badhan","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ijid.2026.109010_bib0036","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/ph18081193","article-title":"Variations in plasma levels of orally administered ivermectin could hamper its potential drug repositioning: results of a bioequivalence study in Mexican population","volume":"18","author":"de la Puente","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijid.2026.109010_bib0037","first-page":"438","article-title":"The effect of food on the pharmacokinetics of oral ivermectin","volume":"75","author":"Duthaler","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.109010_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000236","article-title":"The effect of azithromycin on ivermectin pharmacokinetics\u2013a population pharmacokinetic model analysis","volume":"2","author":"El-Tahtawy","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0039","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/pharmaceutics16091186","article-title":"Pharmacometrics to evaluate dosing of the patient-friendly ivermectin CHILD-IVITAB in children \u2265 15 kg and <15 kg","volume":"16","author":"Golhen","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijid.2026.109010_bib0040","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002237994","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"Guzzo","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2026.109010_bib0041","article-title":"Pharmacokinetics, feasibility and safety of co-administering azithromycin, albendazole, and ivermectin during mass drug administration: a review","volume":"17","author":"McPherson","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0042","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40268-024-00476-4","article-title":"Understanding drug exposure and Trichuris trichiura Cure Rates: a pharmacometric approach for albendazole-ivermectin co-medication in Tanzania and Cote d'Ivoire","volume":"24","author":"Pillay-Fuentes Lorente","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.ijid.2026.109010_bib0043","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1473-3099(24)00751-5","article-title":"Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial","volume":"25","author":"Som\u00e9","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.109010_bib0044","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/jac\/dkaf344","article-title":"Ivermectin dosing for children under 2 years","volume":"80","author":"Yang","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.109010_bib0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12936-017-1923-8","article-title":"Ivermectin susceptibility and sporontocidal effect in Greater Mekong subregion Anopheles","volume":"16","author":"Kobylinski","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.ijid.2026.109010_bib0046","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40572-020-00289-y","article-title":"Little to give, much to gain-what can you do with a dried blood spot?","volume":"7","author":"McClendon-Weary","year":"2020","journal-title":"Curr Environ Health Rep"},{"key":"10.1016\/j.ijid.2026.109010_sbref0047","series-title":"Data for: mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for Bohemia cluster randomized controlled trial","author":"Maia","year":"2023"},{"key":"10.1016\/j.ijid.2026.109010_sbref0048","series-title":"Replication Data for: mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for the Bohemia trial: an open label, randomized controlled clinical trials","author":"Kamau","year":"2023"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226006454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:52:09Z","timestamp":1791816729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226006454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S1201971226006454"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109010","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacometric analyses of various ivermectin dose regimens in Kenya to inform dosing in mass drug administration trials for malaria vector control","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"109010"}}